Skip to main content
. 2017 Dec 22;5(2):e431. doi: 10.1212/NXI.0000000000000431

Figure 3. Analysis of the prognostic value of IL-10–producing B cells or IL-6/IL-10–B-cell ratio measurements in patients with RIS/CIS MS.

Figure 3

(A) Comparison of baseline IL-6/IL-10–producing B-cell ratios between patients with RIS/CIS in whom disease has evolved at 3, 6, 12, and 24 months. (B) Comparison of baseline percentages of IL-10–producing B cells between patients with RIS/CIS in whom disease has evolved at 3, 6, 12, and 24 months. (C) ROC curve representation of IL-10–producing B-cell percentage and IL-6/IL-10–producing B-cell ratio according to the capacity to predict the evolution of the disease. (D) Representative graph of the posttest probability values according to pretest probability values, positive and negative likelihood ratios of IL-6/IL-10–producing B-cell ratio. CIS = clinically isolated syndrome; IL = interleukin; LR+ = positive likelihood ratio; LR− = negative likelihood ratio; RIS = radiologically isolated syndrome; ROC = receiver operating characteristic.